Discontinuing Denosumab and Transitioning to Bisphosphonate Therapy

Critical Safety Considerations

Stopping denosumab without sequential therapy causes rapid bone loss and increased risk of multiple vertebral fractures starting 6-7 months after the last injection, as noted by the European Calcified Tissue Society and other guidelines 1, 2, 3
The European Calcified Tissue Society specifically recommends using a bisphosphonate to reduce this rebound fracture risk when discontinuing denosumab 1, 2
This rebound phenomenon is unique to denosumab and does not occur with bisphosphonates, making transition planning essential 4, 3

Start oral bisphosphonate 6-7 months after the last denosumab dose to prevent rebound bone loss 3
Alendronate 70 mg once weekly is the preferred first-line option due to safety, cost, and efficacy, as recommended by guidelines 1, 5
Alternative oral options include risedronate 35 mg weekly or ibandronate 150 mg monthly 1, 2
IV zoledronic acid 5 mg annually can be considered if oral bisphosphonates are not tolerated 1

The American College of Physicians recommends treating osteoporotic women with pharmacologic therapy for 5 years 6
Continuing treatment beyond achieving osteopenia in the absence of high fracture risk may expose patients to unnecessary medication risks 6
Reassess fracture risk using FRAX to determine if continued pharmacologic therapy is warranted 5
If FRAX shows 10-year hip fracture risk <3% or major osteoporotic fracture risk <20%, and T-score is now >-2.5, discontinuation with transition is appropriate 7, 5

Repeat DXA 12 months after starting bisphosphonate to confirm bone density is maintained or improving 5
Subsequently monitor every 2 years if stable, or annually if there are concerning trends 5
The American College of Physicians recommends against more frequent monitoring during stable treatment 6

Do not simply stop denosumab without sequential therapy, as this can lead to catastrophic rebound vertebral fractures that can occur in clusters 1, 4, 3